C ost-effectiveness analysis has matured to the point that there are often several analyses of a given question in the published literature, each based on a different model. Sometimes the analyses produce similar incremental cost-effectiveness ratios (ICERs), but sometimes the results differ substantially. If the models seem reasonable in their basic construction, why are the answers so different? Is it simply that different data were used to represent the clinical problem or is something else going on?
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In this issue, Drummond, Barbieri, and Wong 1 compare 4 models of rheumatoid arthritis. Two models estimated that infliximab, a new drug, cost £25,000 to £35,000 per quality-adjusted life-year. The others gave higher ICERs, £50,000 to more than £100,000. Drummond and others considered 2 broad categories of model features that might explain the differences: input parameters and model structure. Input parameters can be characterized as the numbers that go into the model-transition probabilities, unit costs, utilities. Model structure refers to the decisions that determine what numbers are needed and in what form: the mathematical type of the model, time horizon and cycle length, treatment regimens compared, and health states. Model structure also encompasses techniques involved in deriving the numbers for the model, what an International Society for Pharmacoeconomics & Outcomes Research task force called "data modeling," 2 such as time-dependent processes 3 and the functional forms used to derive and change probabilities. Working with an electronic copy of 1 low-ICER model, Drummond and others were able to show that the differences between the 2 low-ICER models were explained by input parameters. The high-ICER models were substantially different in structure; working from paper copies of the models and published sensitivity analyses, they were not able to identify why these models produced results so different from the low-ICER models. They concluded that differences in model structure were "more difficult to evaluate" (p 532) than differences in input parameters and, further, that it was difficult to know "whether 1 model structure is 'better' than another" (p 532).
The Institute of Medicine (IOM) recently conducted a similar exercise for 5 published models of colorectal cancer (CRC) screening. 4 The models agreed that CRC screening is cost-effective but disagreed on which of several possible screening strategies was most costeffective. IOM organized a workshop to explore the reasons for the differences. In the best spirit of scholarly cooperation, the modelers estimated results for a series of common scenarios designed by the workshop organizers to standardize input parameters. Input parameters were standardized 1 group at a time: follow-up and surveillance, test performance, costs, and compliance. Standardizing all input parameters produced closer agreement among the models, but when only 1 group was standardized at a time, the results sometimes showed convergence, and sometimes not, suggesting that the input parameters interacted in some way to produce greater agreement when all were standardized. The workshop exercise could not standardize model structure. Indeed, model structure made standardizing input parameters more difficult in that not all the models had the features necessary to incorporate some input parameters.
Decision makers are uneasy about differences that arise from model structure, in part because they do not understand the reasons for the variation. How can modelers evaluate and compare model structures in a persuasive and useful way? As the number of models focused on a particular issue grows, this becomes an increasingly important area for research. Checklists of evaluation criteria help, but good models can differ for legitimate reasons, and some way is needed of evaluating differences and placing them in perspective.
In the current state of the art, model structure primarily involves modeling the natural history of the medical condition and the effects of therapy on it. Modelers routinely compare estimates from their models with outcomes observed in clinical trials, and it would be relatively easy to extend that sort of comparison to several models. Whether the appropriate benchmark is a single definitive trial, several major trials used as independent benchmarks, or summary statistics from a meta-analysis of trials is likely to depend on the type and quality of evidence available for the specific clinical issue. Hawkins and others use a metaanalysis of trials to derive input parameters for their probabilistic analysis of new antiepilepsy drugs. 5 The same approach could provide the data for comparing model structures.
But our knowledge of the natural history of disease and of treatment effects is subject to considerable uncertainty. Uncertainty in parameter estimates is routinely acknowledged in the form of 95% confidence intervals. Hawkins and others 5 (Table 7) report 95% confidence intervals for mean treatment failure probabilities-the upper bound is sometimes 3 or 4 times the lower bound. Variations in model structures can produce results that differ as widely and still fall within some reasonable confidence interval.
Like the uncertainty of input parameters, model uncertainty cannot be eliminated, not only because knowledge about diseases and their treatments will never be perfect but also because the same disease takes a different course in different individuals. Subgroup differences are widely accepted. The premise behind much research on the relation of genomics and proteomics with disease is that diseases may be unique to individuals in nontrivial ways. To support the generalizations needed for clinical practice and policy decisions, models must approximate the disease and its therapeutic processes for populations, generalizing across individual, and sometimes subgroup, heterogeneity. It follows that there will always be uncertainty about the best model structure.
What is needed is a way to describe the probability distribution over model structures for a particular clinical problem, as a basis for evaluating which model structures are probably good approximations and which are probably not. Bayesian terminology talks of the probability distributions of model structures; in application, the term has generally meant what we are calling input parameters here. Perhaps the notion could be expanded to develop probability distributions over the more broadly defined collection of characteristics involved in model structures. Something like the 95% confidence interval, but for a model structure, would be a useful result.
